The role of nephrectomy in metastatic renal cell carcinoma in the immuno‐oncology era

Abstract

Three first line, randomized phase III trials (Keynote 426, Checkmate 9ER and Checkmate 214) relied on predefined statistical criteria to validate the survival advantage of immuno-oncology (IO) based systemic treatment in metastatic renal cell carcinoma (mRCC) relative to Sunitinib. Within each of these three trials, a stratification according to prior nephrectomy was addressed in post-hoc progression free survival (PFS) and overall survival (OS) analyses.